Dimensional Fund Advisors LP Has $1.86 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Dimensional Fund Advisors LP increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 5.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,230 shares of the company’s stock after acquiring an additional 3,624 shares during the quarter. Dimensional Fund Advisors LP’s holdings in BridgeBio Pharma were worth $1,855,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in BBIO. Quarry LP acquired a new position in shares of BridgeBio Pharma during the fourth quarter valued at $50,000. Virtu Financial LLC acquired a new position in BridgeBio Pharma in the fourth quarter valued at about $245,000. Wellington Management Group LLP lifted its stake in BridgeBio Pharma by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 1,495,114 shares of the company’s stock valued at $60,358,000 after buying an additional 75,564 shares during the period. Vanguard Group Inc. lifted its stake in BridgeBio Pharma by 13.5% in the fourth quarter. Vanguard Group Inc. now owns 12,800,294 shares of the company’s stock valued at $516,748,000 after buying an additional 1,524,313 shares during the period. Finally, Nomura Holdings Inc. lifted its stake in BridgeBio Pharma by 9.8% in the fourth quarter. Nomura Holdings Inc. now owns 257,995 shares of the company’s stock valued at $10,415,000 after buying an additional 22,986 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

BBIO has been the topic of several analyst reports. Piper Sandler initiated coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 target price on the stock. Oppenheimer began coverage on BridgeBio Pharma in a report on Thursday, October 3rd. They issued a “market perform” rating for the company. JPMorgan Chase & Co. lowered their price target on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Bank of America restated a “buy” rating and issued a $42.00 price target on shares of BridgeBio Pharma in a report on Wednesday, September 11th. Finally, Evercore ISI lowered their price target on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.92.

BridgeBio Pharma Stock Up 3.8 %

BBIO stock opened at $25.90 on Friday. The business has a 50 day moving average price of $25.95 and a two-hundred day moving average price of $26.79. The company has a market cap of $4.87 billion, a price-to-earnings ratio of -9.85 and a beta of 1.08. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.61. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $3.96 million. The firm’s revenue for the quarter was up 32.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.98) earnings per share. On average, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -2.56 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the completion of the sale, the insider now directly owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $676,234.41. Following the completion of the sale, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at approximately $120,917,867.67. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the sale, the insider now directly owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,831,544 shares of company stock valued at $150,128,821 over the last three months. Insiders own 24.66% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.